Supreme Court divided over legality of patent reviews
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Abbvie (ABBV) PT Raised to $93 at Citi; Remains sidelined
November 29, 2017 8:14 AM ESTCiti raised its price target on Abbvie (NYSE: ABBV) to $93.00 (from $60.00) while maintaining a Neutral rating. Citi upgraded EPS and TP to reflect a more optimistic base case for the timing of US Humira biosimilar entry. However, Citi is unable to become... More
Morgan Stanley Upgrades Allergen (AGN) to Overweight
November 29, 2017 4:16 AM EST(Updated - November 29, 2017 6:56 AM EST)
(updated to add analyst comment)
Morgan Stanley upgraded Allergen (NYSE: AGN) from Equalweight to Overweight with a price target of $200.00.
Analyst David Risinger likes the attractive risk/reward following the recent decline in the... More
